NO20033429L - Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) - Google Patents
Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)Info
- Publication number
- NO20033429L NO20033429L NO20033429A NO20033429A NO20033429L NO 20033429 L NO20033429 L NO 20033429L NO 20033429 A NO20033429 A NO 20033429A NO 20033429 A NO20033429 A NO 20033429A NO 20033429 L NO20033429 L NO 20033429L
- Authority
- NO
- Norway
- Prior art keywords
- ikk
- kappa
- kinase
- inhibitors
- methods
- Prior art date
Links
- 102000001284 I-kappa-B kinase Human genes 0.000 title 2
- 108060006678 I-kappa-B kinase Proteins 0.000 title 2
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26585301P | 2001-02-01 | 2001-02-01 | |
| US09/965,977 US6960585B2 (en) | 2000-10-03 | 2001-09-27 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| PCT/US2002/003060 WO2002060386A2 (en) | 2001-02-01 | 2002-02-01 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033429D0 NO20033429D0 (no) | 2003-07-31 |
| NO20033429L true NO20033429L (no) | 2003-09-24 |
Family
ID=26951465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033429A NO20033429L (no) | 2001-02-01 | 2003-07-31 | Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1363993A4 (cs) |
| JP (1) | JP2004529088A (cs) |
| AU (1) | AU2002247059B2 (cs) |
| CA (1) | CA2436770A1 (cs) |
| CZ (1) | CZ20032287A3 (cs) |
| HU (1) | HUP0304045A3 (cs) |
| MX (1) | MXPA03006817A (cs) |
| NO (1) | NO20033429L (cs) |
| PL (1) | PL364111A1 (cs) |
| WO (1) | WO2002060386A2 (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2424303A1 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| JP4285602B2 (ja) | 2000-10-26 | 2009-06-24 | アムジェン インコーポレイテッド | 抗炎症剤 |
| WO2003048152A2 (en) | 2001-12-05 | 2003-06-12 | Tularik Inc. | Inflammation modulators |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| MX2007016541A (es) | 2005-06-30 | 2008-03-07 | Smithkline Beecham Corp | Compuestos quimicos. |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| WO2007030362A1 (en) * | 2005-09-07 | 2007-03-15 | Laboratoires Serono Sa. | Ikk inhibitors for the treatment of endometriosis |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| CA2721927C (en) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| WO2010000903A2 (es) * | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis |
| JP5312466B2 (ja) | 2008-10-02 | 2013-10-09 | 旭化成ファーマ株式会社 | ８位置換イソキノリン誘導体及びその用途 |
| EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160097A (en) * | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
| US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| US6030834A (en) * | 1997-12-30 | 2000-02-29 | Chiron Corporation | Human IKK-beta DNA constructs and cells |
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| DE60141895D1 (de) * | 2000-03-15 | 2010-06-02 | Sanofi Aventis Deutschland | Substituierte beta-carboline mit ikb-kinase hemmender wirkung |
| CA2424303A1 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
-
2002
- 2002-02-01 HU HU0304045A patent/HUP0304045A3/hu unknown
- 2002-02-01 EP EP02714815A patent/EP1363993A4/en not_active Withdrawn
- 2002-02-01 MX MXPA03006817A patent/MXPA03006817A/es active IP Right Grant
- 2002-02-01 AU AU2002247059A patent/AU2002247059B2/en not_active Ceased
- 2002-02-01 CZ CZ20032287A patent/CZ20032287A3/cs unknown
- 2002-02-01 WO PCT/US2002/003060 patent/WO2002060386A2/en active Application Filing
- 2002-02-01 PL PL02364111A patent/PL364111A1/xx not_active Application Discontinuation
- 2002-02-01 JP JP2002560582A patent/JP2004529088A/ja active Pending
- 2002-02-01 CA CA002436770A patent/CA2436770A1/en not_active Abandoned
-
2003
- 2003-07-31 NO NO20033429A patent/NO20033429L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1363993A4 (en) | 2008-11-12 |
| AU2002247059B2 (en) | 2006-11-16 |
| PL364111A1 (en) | 2004-12-13 |
| JP2004529088A (ja) | 2004-09-24 |
| WO2002060386A2 (en) | 2002-08-08 |
| MXPA03006817A (es) | 2003-11-13 |
| NO20033429D0 (no) | 2003-07-31 |
| EP1363993A2 (en) | 2003-11-26 |
| CZ20032287A3 (cs) | 2004-02-18 |
| HUP0304045A2 (hu) | 2004-04-28 |
| CA2436770A1 (en) | 2002-08-08 |
| WO2002060386A3 (en) | 2002-10-10 |
| HUP0304045A3 (en) | 2005-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033429L (no) | Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) | |
| NO20025814D0 (no) | Fremgangsmåte ved brönnfullföring | |
| NO20035426L (no) | Fremgangsmate ved administrering av anti-TNF-D-antistoff | |
| NO20031489D0 (no) | Fremgangsmåte og anordning ved trekkbar broplugg | |
| NO20003775D0 (no) | FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner | |
| DK1352895T3 (da) | Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme | |
| NO20052760D0 (no) | Fremgangsmate for behandling av kreft og beslektede fremgangsmater. | |
| IS8451A (is) | Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma | |
| IS8410A (is) | Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma | |
| NO20030265L (no) | Fremgangsmater ved behandling av borebronner | |
| NO20044112L (no) | Fremgangsmate ved induksjon av terminal differensiering | |
| DK1463683T3 (da) | Fremgangsmåde og arrangement ved ladesøjle | |
| IS7684A (is) | Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand | |
| NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
| EP1539248A4 (en) | INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER | |
| NO20014648D0 (no) | Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer | |
| NO20033498L (no) | Fremgangsmåte for behandling og törking av trevirke | |
| NO20042012L (no) | Sammensetning og fremgangsmate for behandling av diabetes | |
| NO20033506L (no) | Parasitticidale preparater og metoder for anvendelse | |
| NO20024867D0 (no) | Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler | |
| NO334788B2 (no) | Fremgangsmåte for behandling av søvnløshet | |
| NO20023737D0 (no) | Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse | |
| DK1381620T3 (da) | Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer | |
| NO20033541D0 (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer | |
| NO20034246D0 (no) | Enkel dose av aromataseinhibitor for behandling av ufruktbarhet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |